Peter Lankau - ANI Pharmaceuticals Director

ANIP Stock  USD 65.43  0.71  1.07%   

Director

Mr. Peter A. Lankau is Director of ANI Pharmaceuticals Inc. Mr. Lankau is a principal in the consulting firm Lankau Consulting LLC which provides advisory and consulting services to support boards of directors and senior management of pharmaceutical and biotechnology companies as well as VC and private equity firms. He is Chairman of the board of Phosphagenics Limited an Australian researchbased biotechnology company. Prior to that Mr. Lankau was Executive Chairman at Nautilus Neurosciences Inc. a private neurologyfocused specialty pharmaceutical company. Prior to Nautilus Mr. Lankau was Chairman and CEO of Logical Therapeutics Inc. a venture backed development stage biopharmaceutical company and was President Chief Executive Officer and Director of Endo Pharmaceuticals Inc. a publicly traded specialty pharmaceutical company. Mr. Lankau also currently serves on the board of Advisors of Orchard Venture Partners a life sciences VC firm. since 2015.
Age 60
Tenure 9 years
Address 210 Main Street West, Baudette, MN, United States, 56623
Phone218 634 3500
Webhttps://www.anipharmaceuticals.com

ANI Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0372 % which means that it generated a profit of $0.0372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0472 %, meaning that it created $0.0472 on every $100 dollars invested by stockholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/25/2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.07. At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 04/25/2024, Liabilities And Stockholders Equity is likely to grow to about 949.6 M, while Non Current Liabilities Other is likely to drop slightly above 14.4 M.
The company currently holds 315.33 M in liabilities with Debt to Equity (D/E) ratio of 0.86, which is about average as compared to similar companies. ANI Pharmaceuticals has a current ratio of 3.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ANI Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, ANI Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ANI Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ANI to invest in growth at high rates of return. When we think about ANI Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Richard EdlinEagle Pharmaceuticals
57
Nancy SnydermanAlkermes Plc
66
Ravi BhoothalingamDr Reddys Laboratories
68
Gary LyonsNeurocrine Biosciences
66
Eric PaquesINC Research Holdings
61
Paul MitchellAlkermes Plc
64
Gerald CarlsonPhibro Animal Health
75
Lennie MichelsonINC Research Holdings
38
Richard PrinsAmphastar P
61
William KlitgaardINC Research Holdings
63
Charles HinkatyPrestige Brand Holdings
64
Douglas BraunsteinEagle Pharmaceuticals
57
Mark KronenfeldPacira Pharmaceuticals
63
Yvonne GreenstreetPacira Pharmaceuticals
55
David BurgstahlerINC Research Holdings
47
Nancy WysenskiAlkermes Plc
60
David NortonINC Research Holdings
65
Theodore SchroederCollegium Pharmaceutical
63
Shikha SharmaDr Reddys Laboratories
62
Gino SantiniCollegium Pharmaceutical
61
Jon DuaneIronwood Pharmaceuticals
59
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 601 people. ANI Pharmaceuticals (ANIP) is traded on NASDAQ Exchange in USA. It is located in 210 Main Street West, Baudette, MN, United States, 56623 and employs 642 people. ANI Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

ANI Pharmaceuticals Leadership Team

Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Nash, Independent Director
Elizabeth JD, Chief Disease
Charlotte Arnold, CFO, Vice President
Daniel Raynor, Director
Stephen Carey, CFO, Vice President
David Sullivan, VP of Quality Operations
Muthusamy RPh, COO RD
Nikhil Lalwani, CEO President
Thomas Haughey, Independent Director
Patrick Walsh, Independent Director
Chad Gassert, Senior Strategy
Ori Gutwerg, Senior Generics
Fred Holubow, Independent Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO and President and Director
Thomas Penn, Director
Mary MD, Chief Officer
Robert Brown, Chairman of the Board
Mark Ginski, Vice President of Corticotropin Product Development
Robert Schrepfer, VP of New Bus. Devel. and Contract Manufacturing
Krista Davis, Senior Officer
Meredith Cook, General VP
Karen Quinn, Vice President - Corticotropin Regulatory Affairs
James Marken, Senior Development
Peter Lankau, Director
Christopher Mutz, Senior Disease

ANI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ANI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ANI Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ANI Pharmaceuticals' short interest history, or implied volatility extrapolated from ANI Pharmaceuticals options trading.

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with ANI Stock

  0.9VKTX Viking Therapeutics Potential GrowthPairCorr
  0.94ELEV Elevation Oncology Earnings Call This WeekPairCorr

Moving against ANI Stock

  0.69ZURA Zura Bio Limited Financial Report 10th of May 2024 PairCorr
  0.58GILD Gilead Sciences Earnings Call TodayPairCorr
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ANI Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if ANI Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Ani Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Ani Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for ANI Stock analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.89)
Earnings Share
0.85
Revenue Per Share
27.044
Quarterly Revenue Growth
0.397
Return On Assets
0.0372
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.